Combined RNA Interference of Hexokinase II and ¹³¹I-Sodium Iodide Symporter Gene Therapy for Anaplastic Thyroid Carcinoma

Abstract

Our results suggest that the combined HKII shRNA and (131)I therapy has a stronger antitumor effect than either the (131)I therapy or the HKII shRNA alone. Therefore, this combined therapy could be used as a powerful strategy for treating anaplastic thyroid carcinoma.